Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Exploratory evaluation of safety, tolerability, pharmacokinetics (PK), maximum tolerated dose
(MTD), and efficacy of BI 2536 administered in combination with pemetrexed